Lexicon Pharmaceuticals, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

528872302
SEDOL

BWFZX59
CIK

0001062822

www.lexpharma.com
LEI:
FIGI: BBG000BQ85G2
LXRX

Lexicon Pharmaceuticals, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Lexicon Pharmaceuticals, Inc.
ISIN
US5288723027
TICKER
LXRX
MIC
XNAS
REUTERS
LXRX.OQ
BLOOMBERG
LXRX US
EN 728x90
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Thu, 31.10.2024

PDUFA target action date set for December 20, 2024
PDUFA target action date set for December 20, 2024
Wed, 23.10.2024

Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD)
Post hoc analysis evaluated sotagliflozin in patients with diabetic kidney disease (DKD)
Wed, 16.10.2024

-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments
-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments
Fri, 27.09.2024

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population

Mon, 16.09.2024

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.

Tue, 10.09.2024

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin  

Wed, 21.08.2024

Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024

Wed, 07.08.2024

THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Thu, 25.07.2024

THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Mon, 08.07.2024

Jeff Wade Named President and Chief Operating Officer
Jeff Wade Named President and Chief Operating Officer
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements